Although there is room to improve the efficacy and utility of ICIs, their success in a subset of NSCLC patients suggests that the development of additional ICIs holds great promise to benefit those who are ineligible, do not respond, or become resistant to CTLA-4 and PD-1/PD-L1 blockade. Here, CTLA4 is linked to non-small cell lung carcinoma.